Observational studyMedicine2025
High prevalence of primary aldosteronism in a tertiary care hospital in Lebanon.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood pressure patterns and cardio-renal complications in primary aldosteronism compared with essential hypertension in a tunisian population.Journal of human hypertension · 2026Article
- Evaluating 24-h Urine Aldosterone Levels as a Practical Diagnostic Tool for Primary Aldosteronism.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is a frequent cause of secondary hypertension. Studies on the prevalence of PA are lacking in the Middle East region. To determine the proportion of patients with high aldosterone-to-renin ratio (ARR) among Lebanese patients with hypertension screened for PA and to compare their clinical and biological characteristics with patients with essential hypertension. A retrospective review of medical charts of patients with hypertension undergoing sampling of serum aldosterone and plasma renin concentration at a tertiary care center between October 2022 and 2023 was conducted. Of 144 patients with hypertension screened for PA, 23 (16%) had an ARR higher than 3.7 ng/dL/mU/L and serum aldosterone above 15 ng/dL. The mean age of the screened population was 51 ± 15 years, 56% were men. The median duration of hypertension was 4 years and the median number was 2 of antihypertensive medications. Patients with a positive screening test were mostly men (88%, P = .0001), and more frequently had diabetes (50%, P < .0001) than those with essential hypertension. Only 22% had hypokalemia. Of the 23 patients, 11 underwent intravenous saline suppression testing; PA was confirmed in all of them. The high frequency of PA in our center is comparable to other countries. More studies are needed to determine how to reduce healthcare disparities and overcome the barriers to appropriate diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.